| Health / Medical Topics |
MUC1 Peptide-Poly-ICLC Vaccine
A vaccine preparation containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. Upon administration, MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1, a tumor associated antigen normally present on the lining of the human colon, may be overexpressed and/or mutated in a variety of cancer cell types. The adjuvant poly-ICLC, a ligand for toll-like receptor-3, induces the release of cytokines which may help boost the immune response against MUC1. (NCI Thesaurus)
YOU MAY ALSO LIKE
This gene plays a role in cellular signal transduction and is used as a biomarker for breast cancer.
A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory…
A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1…
MUC-1 antigen is a mammary-type apomucin, a high molecular weight transmembrane glycoprotein, of which the extracellular domain is formed by a repeating…
A protein found on certain epithelial cells, which line the inside and outside surfaces of the body. It may be found in…
A clonal disorder characterized by the secretion of a mu heavy chain that lacks a variable region. Most patients present with…
